Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.99% is 40% above its 5-year average of 1.42%, around the middle of its 5-year range (0.00%–3.72%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.46% below its 12-month average of 2.08%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.99%.
DEBT TO ASSETS RATIO
1.99%
DEBT TO ASSETS RATIO AVG TTM
2.08%
DEBT TO ASSETS RATIO AVG 3Y
1.24%
DEBT TO ASSETS RATIO AVG 5Y
1.42%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-4.46%
CURRENT VS 3Y AVG
+60.57%
CURRENT VS 5Y AVG
+40.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 835 covered companies
CURRENT VS SECTOR MEDIAN
+2106.99%
vs the sector median at left
Amylyx Pharmaceuticals, Inc.
Market Cap
$3.07B
Debt to Assets Ratio
1.99%
TTM Avg
2.08%
3Y Avg
1.24%
5Y Avg
1.42%
Market Cap
$3.08B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.01B
Debt to Assets Ratio
0.23%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.99B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.19B
Debt to Assets Ratio
0.15%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.29B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.82B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.80B
Debt to Assets Ratio
0.59%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.07B | 1.99% | 2.08% | 1.24% | 1.42% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.08B | 0.02% | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.01B | 0.23% | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.99B | 0.00% | N/A | N/A | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 0.15% | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.29B | 0.04% | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.82B | 0.02% | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | 0.59% | N/A | N/A | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 0.11% | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.39B | 0.04% | N/A | N/A | N/A |
Debt/Assets
2.0%
Debt/Equity
0.02
Current Ratio
12.12
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.99% |
| 2026-03-31 | 1.92% |
| 2025-12-31 | 1.79% |
| 2025-09-30 | 1.64% |
| 2025-06-30 | 3.06% |
| 2025-03-31 | 0.63% |
| 2024-12-31 | 1.02% |
| 2024-09-30 | 1.02% |
| 2024-06-30 | 0.95% |
| 2024-03-31 | 0.88% |
| 2023-12-31 | 0.82% |
| 2023-09-30 | 1.02% |
| 2023-06-30 | 1.17% |
| 2023-03-31 | 1.42% |
| 2022-12-31 | 1.60% |
| 2022-09-30 | 3.72% |
| 2022-06-30 | 3.14% |
| 2022-03-31 | 2.62% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.20% |
